Pharmacist Discharge Medication Reconciliation Study

This study has been completed.
Sponsor:
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01226589
First received: October 21, 2010
Last updated: April 18, 2011
Last verified: April 2011
  Purpose

Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the CCI. The purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.


Condition Intervention
Medication Reconciliation
Procedure: MRS

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • MRS Correlation with Treatment Response. [ Time Frame: up to 1 year ]
    The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute


Secondary Outcome Measures:
  • Correlation with Tumor Stage [ Time Frame: up to 1 year ]
    The amount of medication discrepancies after discharge that has the potential to cause moderate harm to severe harm.

  • The frequency of each type of unintentional medication discrepancies.

Estimated Enrollment: 50
Study Start Date: October 2007
Study Completion Date: October 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cancer inpatients under the care of Dr. Follett or Dr. Candler
  • Cancer inpatients to be discharged from the CCI
  • Patients >18 years of age
  • Patients that are taking >1 medications or herbals total at home.

Exclusion Criteria:

  • Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron patients or patients receiving radiation treatment for thyroid)
  • Patients that do not remain in hospital >72 hours
  • Patients without a home phone number or equivalent contact number.
  • Language barrier (patients unable to speak or understand English).
  • Patients that are readmitted and already included into the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01226589

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Carole Chambers, BSc. Pharmacy AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: Carole Chambers, Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT01226589     History of Changes
Other Study ID Numbers: 23851
Study First Received: October 21, 2010
Last Updated: April 18, 2011
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
Cancer cancer
MRS
Treatment response
Histologically confirmed diagnosed Breast cancer.
Patient is 18 years or older.
Karnofsky performance score is equal to or greater than 70.
No previously irradiated or recurrent breast.
No contraindication to MRS/MRI.

ClinicalTrials.gov processed this record on July 26, 2014